↓ Skip to main content

Preclinical Testing of a Novel Niclosamide Stearate Prodrug Therapeutic (NSPT) Shows Efficacy Against Osteosarcoma

Overview of attention for article published in Molecular Cancer Therapeutics, May 2020
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
5 news outlets
twitter
8 tweeters

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
11 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Preclinical Testing of a Novel Niclosamide Stearate Prodrug Therapeutic (NSPT) Shows Efficacy Against Osteosarcoma
Published in
Molecular Cancer Therapeutics, May 2020
DOI 10.1158/1535-7163.mct-19-0689
Pubmed ID
Authors

Gireesh B. Reddy, David L. Kerr, Ivan Spasojevic, Artak Tovmasyan, David S. Hsu, Brian E. Brigman, Jason A. Somarelli, David Needham, William C. Eward

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 36%
Student > Bachelor 3 27%
Student > Doctoral Student 1 9%
Unknown 3 27%
Readers by discipline Count As %
Medicine and Dentistry 3 27%
Chemistry 2 18%
Pharmacology, Toxicology and Pharmaceutical Science 1 9%
Biochemistry, Genetics and Molecular Biology 1 9%
Unknown 4 36%

Attention Score in Context

This research output has an Altmetric Attention Score of 44. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 January 2022.
All research outputs
#702,609
of 20,739,472 outputs
Outputs from Molecular Cancer Therapeutics
#79
of 3,545 outputs
Outputs of similar age
#19,815
of 295,712 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#2
of 31 outputs
Altmetric has tracked 20,739,472 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,545 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 295,712 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.